JEANETTE'S STORY

Hi! I'm Jeanette Bolden... For those of you who don't know me; I am the head coach for the 2008 U.S. Olympic Women's Track and Field team. I am also the head coach for the UCLA Women's Track and Field team. 2008 is going to be a very exciting year for me both on and off the track; I'm gearing up to lead the Olympic team to "go for the gold" in Beijing this summer. A former gold medal runner myself, I'm excited to help bring the team to victory!

Off the track, I am a wife and mother of two who has struggled with allergic asthma since early childhood. Growing up, I felt my full potential was compromised with the symptoms I suffered in my everyday life. During my track career, I was able to win races, but I always had my inhaler tucked away in my sock!

Why am I telling you all of this?

Well, I used to be among the 10 million asthma sufferers in the United States who feel their asthma is uncontrolled. I was able to take control of my asthma by working with an

asthma specialist who identified the underlying cause of my asthma and developed an asthma management plan that was right for me. I was surprised when I learned that the majority of people with asthma don't see a specialist and that, despite treatment, many people continue to experience symptoms and lead lives compromised by their asthma.

I hope that by sharing my story I will encourage others who live with asthma to talk with an asthma specialist, understand their asthma triggers and get their asthma on track.

next >

page
1
2

Who is XOLAIR For?

XOLAIR (Omalizumab) For Subcutaneous Use is a prescription medicine given by injection for people who are 12 years of age and above who have moderate to severe persistent asthma that is triggered by year-round allergens in the air. A simple skin or blood test will confirm that a patient has this kind of asthma. This is known as allergic asthma. XOLAIR helps reduce the number of asthma attacks in people with allergic asthma who still have asthma symptoms even though they are taking inhaled steroids. XOLAIR has not been proven to work in other allergic conditions.

Important Safety Information

XOLAIR (Omalizumab) For Subcutaneous Use should always be injected in a doctor's office. You should read the Medication Guide before starting XOLAIR treatment and before each and every treatment.

A severe allergic reaction called anaphylaxis has happened in some patients after they received XOLAIR. Anaphylaxis is a life-threatening condition. Seek emergency medical treatment right away if symptoms occur. Signs and symptoms of anaphylaxis include:

- wheezing, shortness of breath, cough, chest tightness, or trouble breathing

- low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of "impending doom"

- flushing, itching, hives, or feeling warm

- swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing

You should not receive XOLAIR if you have ever had an allergic reaction to a XOLAIR injection. Do not use XOLAIR if you are allergic to any of its ingredients.

In clinical studies, 0.5% of patients receiving XOLAIR developed cancer, compared to 0.2% of patients receiving placebo injections.

In clinical studies, the most common side effects in patients receiving XOLAIR included injection-site reactions (45%), viral infections (23%), upper respiratory tract infection (20%), sinus infection (16%), headache (15%), and sore throat (11%).

Do not change or stop taking any of your other asthma medicines unless your healthcare provider tells you to do so. You may not see an immediate improvement in your asthma when beginning XOLAIR therapy.

Talk to your doctor for more information and if you have any questions about your treatment.

Please see full Prescribing Information and the Medication Guide for additional important information.

tell a friend

Asthma On Track is supported by Genentech, Inc. & Novartis Pharmaceuticals Corporation

For more information please visit xolair.com